4Nakao S. Immune mechanism of aplastic anemia[J]. Int J Hematol, 1997,66(2) : 127 - 134.
5Mentzel U, VOget H, Rossol R et al. Analysis of lymphoeyte subsets in patient with AA before and during immuno suppressive therapy. Ann Haematol, 1993,66 (3) : 127.
7Maciejewski JP, Hibbs JR, Anderson S, et al. Bone marrow and peripheral blood lymphocyte phenotype in patients with bone marrow failure. Exp Hematol, 1994,22 : 1102 - 1110.
8Niedbala W, WeiXQ, Canlpbell C, et al. Nitdc oxide pefferentially indaces type I T cell differentiation by selectively up- regulatry IL- 12 receptor β2 expression via cGMP[J] .Proc Natl Acad Sci USA,20(O ,99(25) : 16186 - 16191.
9Demeter J, Messer G, Schrezenmeier H, et al. Clinical relevance of the TNF- alpha promoter/enhancer polymorphism in patients with aplastic anemia [ J ], Ann Hematol, 2002, 81 (10) : 566 -569.
10Platani AS, Dhuik K, Sam J, et al. Alteration in lymphocytephenoty and lymphokine in patients with aplastic anemia following antithymocyteglobulin (IPG) therany [ J ]. Blood, 1998,66(2) :347 - 351.
